Senzime

Uppsala, July 3, 2023. Senzime AB (publ) a leader in the field of peri- and post-operative patient monitoring solutions, today announced a new study validating the feasibility of TetraSens pediatric disposable sensor. The study was performed at the Nationwide Children’s Hospital, Columbus, US, and evaluated Senzime’s TetraGraph using the TetraSens Pediatric sensor. The study demonstrated that the TetraGraph system can be used in infants and children, even those who weigh less than 10 kilograms.

Quantitative Train-of-Four (TOF) neuromuscular monitoring has seen limited use in infants and children, primarily due to lack of adequate technology and effective equipment. The recently published study Intraoperative electromyographic monitoring in children using a novel pediatric sensor included 51 patients who ranged in age from 0.2 to 7.9 years and in weight from 4.2 to 36.0 kilograms. The study concludes that neuromuscular monitoring can be performed intraoperatively in pediatric patients who are less than 8 years of age using a novel commercially available EMG‐based monitor (TetraGraph) with a recently developed pediatric sensor (TetraSens Pediatric).

“This is the first clinical study that validates and proves the feasibility of a pediatric and portable EMG-based neuromuscular monitoring dedicated to small children. The study confirms the clinical advantage of our pediatric solution, even on very small and delicate infants,” commented Philip Siberg, CEO of Senzime.

References

Kalsotra S, Rice‐Weimer J, Tobias JD. Intraoperative electromyographic monitoring in children using a novel pediatric sensor. Saudi J Anaesth 2023;17:378‐82. June 2022.